Evidence map›Paper›PMID 34944608›Full record

ArticleBiomedicines2021

Analysis of Parainflammation in Chronic Glaucoma Using Vitreous-OCT Imaging.

María Jesús Rodrigo, Manuel Subías, Alberto Montolío, Silvia Méndez-Martínez, Teresa Martínez-Rincón, Lorena Arias, David García-Herranz, Irene Bravo-Osuna, Julian Garcia-Feijoo, Luis Pablo and 6 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

María Jesús RodrigoDepartment of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-4009-3075
Manuel SubíasDepartment of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-2344-016X
Alberto MontolíoBiomaterials Group, Aragon Engineering Research Institute (I3A), University of Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0001-7248-4399
Silvia Méndez-MartínezDepartment of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
Teresa Martínez-RincónDepartment of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0002-8891-0417
Lorena AriasDepartment of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
David García-HerranzInnovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid (UCM), 28040 Madrid, Spain.ORCID 0000-0003-2092-5927
Irene Bravo-OsunaUniversity Institute of Industrial Pharmacy (IUFI), School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0003-3133-7872
Julian Garcia-FeijooDepartment of Ophthalmology, San Carlos Clinical Hospital, UCM, 28040 Madrid, Spain.
Luis PabloDepartment of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
José CegoñinoBiomaterials Group, Aragon Engineering Research Institute (I3A), University of Zaragoza, 50018 Zaragoza, Spain.
Rocio Herrero-VanrellNational Ocular Pathology Network (OFTARED), Carlos III Health Institute, 28040 Madrid, Spain.ORCID 0000-0001-9764-7975
Ana CarreteroCentre for Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Jesus RuberteCentre for Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Elena Garcia-MartinDepartment of Ophthalmology, Miguel Servet University Hospital, 50009 Zaragoza, Spain.ORCID 0000-0001-6258-2489
Amaya Pérez Del PalomarBiomaterials Group, Aragon Engineering Research Institute (I3A), University of Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0003-0669-777X
Hospital Universitario Miguel Servet · ESInstituto de Salud Carlos III · ESUniversidad Complutense de Madrid · ESUniversidad de Zaragoza · ESUniversitat Autònoma de Barcelona · ESHospital Clínico San Carlos · ES

Funding

Instituto de Salud Carlos III M17/00213Instituto de Salud Carlos III PI17/01726Instituto de Salud Carlos III PI17/01946Instituto de Salud Carlos III PI20/00437Ministry of the Interior MAT2017-83858-C2-2Ministry of the Interior PID2020-113281RB-C2-2
6 · The paper itself

Abstract

Glaucoma causes blindness due to the progressive death of retinal ganglion cells. The immune response chronically and subclinically mediates a homeostatic role. In current clinical practice, it is impossible to analyse neuroinflammation non-invasively. However, analysis of vitreous images using optical coherence tomography detects the immune response as hyperreflective opacities. This study monitors vitreous parainflammation in two animal models of glaucoma, comparing both healthy controls and sexes over six months. Computational analysis characterizes in vivo the hyperreflective opacities, identified histologically as hyalocyte-like Iba-1+ (microglial marker) cells. Glaucomatous eyes showed greater intensity and number of vitreous opacities as well as dynamic fluctuations in the percentage of activated cells (50-250 microns

Indexed as

animal modelsbiomedical imagingglaucomaimage analysis and processinginflammationoptical coherence tomographyvitreous body

Identifiers

PMID34944608
PMCPMC8698891
OpenAlexW3214736355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.